Chemistry:ARO-APOC3

From HandWiki
Revision as of 10:16, 8 February 2024 by John Marlo (talk | contribs) (correction)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

ARO-APOC3 is an apolipoprotein C-III antagonist and RNAi therapeutic investigated for dyslipidemia and familial chylomicronemia syndrome.[1][2]

References

  1. ↑ Hegele, Robert A (November 2022). "APOC3 Interference for Familial Chylomicronaemia Syndrome". TouchREVIEWS in Endocrinology 18 (2): 82–83. doi:10.17925/EE.2022.18.2.82. ISSN 2752-5457. PMID 36694895. 
  2. ↑ Clifton, Peter; Sullivan, David; Baker, John; Schwabe, Christian; Thackwray, Susan; Scott, Russell; Hamilton, James; Lira Pineda, Armando J et al. (16 November 2021). "Abstract 10357: ARO-APOC3, an Investigational RNAi Therapeutic, Shows Similar Efficacy and Safety in Genetically Confirmed FCS and Non-FCS Participants with Severe Hypertriglyceridemia". Circulation 144 (Suppl_1). doi:10.1161/circ.144.suppl_1.10357. 



Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:ARO-APOC3&oldid=3422426"